BR112012019199A2 - derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio. - Google Patents

derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio.

Info

Publication number
BR112012019199A2
BR112012019199A2 BR112012019199A BR112012019199A BR112012019199A2 BR 112012019199 A2 BR112012019199 A2 BR 112012019199A2 BR 112012019199 A BR112012019199 A BR 112012019199A BR 112012019199 A BR112012019199 A BR 112012019199A BR 112012019199 A2 BR112012019199 A2 BR 112012019199A2
Authority
BR
Brazil
Prior art keywords
azacycloalkyl
channel modulators
potassium channel
anilide derivatives
potassium
Prior art date
Application number
BR112012019199A
Other languages
English (en)
Inventor
Gary Lee Larson
Huanming Chen
Jean-Michel Vernier
Jim Zhen Wu
Lan Wayne Cheney
Martha Delarosa
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of BR112012019199A2 publication Critical patent/BR112012019199A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

derivados de 4-(n-azacicloalquil) aniilidos como moduladores de canais de potássio, esta invenção provê um composto da fóormula ia onde x= 0 ou s; y é 0 ou s; q= 1 ou 0; e outros substituintes são definidos aqui. tais compostos podem afetar a abertura de, ou de outro modular, os canais de potássio dependentes de voltagem. tais compostos são utilizãveis para o tratamento e prevenção de doenças e distúrbios que são afetados pela ativação ou modulação dos canais de íon potássio. uma de tais condições são distúrbios convulsivos.
BR112012019199A 2010-02-01 2011-01-25 derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio. BR112012019199A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/698,070 US8993593B2 (en) 2006-08-23 2010-02-01 N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PCT/US2011/022345 WO2011094186A1 (en) 2010-02-01 2011-01-25 Derivatives of 4-(n-azacycloalkyl) aniilides as potassium channel modulators

Publications (1)

Publication Number Publication Date
BR112012019199A2 true BR112012019199A2 (pt) 2017-01-17

Family

ID=44319712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019199A BR112012019199A2 (pt) 2010-02-01 2011-01-25 derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio.

Country Status (12)

Country Link
US (1) US8993593B2 (pt)
EP (1) EP2531024A4 (pt)
JP (1) JP5844285B2 (pt)
KR (1) KR101841989B1 (pt)
CN (1) CN102869250A (pt)
AU (1) AU2011209731A1 (pt)
BR (1) BR112012019199A2 (pt)
CA (1) CA2788712C (pt)
EA (1) EA201290748A1 (pt)
MX (1) MX2012008969A (pt)
SG (1) SG182799A1 (pt)
WO (1) WO2011094186A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
EP2986603A1 (en) 2013-04-19 2016-02-24 Oslo Universitetssykehus HF Radiolabeled gnrh antagonists as pet imaging agents
CN109641836A (zh) 2016-06-10 2019-04-16 赛弗卢尔生命科学公司 氟化的2-氨基-4-(取代的氨基)苯基氨基甲酸酯衍生物
FI3790548T3 (fi) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi
TW202128627A (zh) 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
EP4054580A1 (en) 2019-11-08 2022-09-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
KR20220113411A (ko) 2019-12-06 2022-08-12 제논 파마슈티칼스 인크. KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
US20210213009A1 (en) * 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia
WO2022173853A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
EP4074696A4 (en) * 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma Inc POTASSIUM CHANNEL REGULATOR COMPOUND, PRODUCTION AND USE THEREOF
CN113698345B (zh) 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
TW202333693A (zh) * 2021-12-31 2023-09-01 大陸商上海翰森生物醫藥科技有限公司 苯并哌啶衍生物調節劑、其製備方法和應用
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US725511A (en) * 1902-10-07 1903-04-14 John Thomson Press Company Apparatus for securing ink-distributing cylinders to platen printing-press.
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3369315D1 (en) 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
ATE43789T1 (de) 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (pt) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
EP1634597A1 (en) 1994-09-22 2006-03-15 Richard Alan Smith Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
ATE300308T1 (de) 1994-12-12 2005-08-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
WO1999007411A1 (fr) 1997-08-08 1999-02-18 Chugai Seiyaku Kabushiki Kaisha Remedes contre les complications du diabete
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
HUP0104676A3 (en) 1998-12-14 2005-12-28 Cellegy Pharmaceuticals Inc So Compositions for the treatment of anorectal disorders and their use
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
WO2000053225A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1163225A1 (en) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
DK1200073T3 (da) 1999-07-06 2007-05-07 Lilly Co Eli Selektive iGluR5-receptorantagonister til behandling af migræne
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003506388A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
DE60037321D1 (de) 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AU2002338333A1 (en) 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (en) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
CA2505195C (en) 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
CA2511502A1 (en) 2002-12-27 2004-07-15 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives,useful for treating disorders of the central nervous system
EP1606247A1 (en) 2003-03-14 2005-12-21 H. Lundbeck A/S Substituted aniline derivatives
CA2519582A1 (en) 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
EP1631546A1 (en) 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004105795A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
WO2005100349A2 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
JP2007536229A (ja) 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JPWO2006054513A1 (ja) 2004-11-19 2008-05-29 キッセイ薬品工業株式会社 神経因性疼痛の予防又は治療剤
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
MX2009002002A (es) 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.

Also Published As

Publication number Publication date
US8993593B2 (en) 2015-03-31
US20110003850A1 (en) 2011-01-06
KR101841989B1 (ko) 2018-03-26
CA2788712C (en) 2018-09-11
CN102869250A (zh) 2013-01-09
SG182799A1 (en) 2012-09-27
EP2531024A4 (en) 2013-06-19
JP2013518815A (ja) 2013-05-23
WO2011094186A1 (en) 2011-08-04
EP2531024A1 (en) 2012-12-12
CA2788712A1 (en) 2011-08-04
AU2011209731A1 (en) 2012-08-23
EA201290748A1 (ru) 2013-04-30
JP5844285B2 (ja) 2016-01-13
MX2012008969A (es) 2012-09-07
KR20120123695A (ko) 2012-11-09

Similar Documents

Publication Publication Date Title
BR112012019199A2 (pt) derivados de 4-(n-azacicloalquil) anilidas como moduladores de canais de potássio.
MX2009002002A (es) Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
BR112014030386A2 (pt) compostos e composições para modular a atividade de egfr
MX2020004534A (es) Moduladores de la vía integrada del estrés.
MX2020004538A (es) Moduladores de la vía de estrés integrada.
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
MX2020004556A (es) Moduladores de la vía de estrés integrada.
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
BR112015032595A2 (pt) inibidores de ido
EA201300887A1 (ru) Модуляторы s1p
BR112015028017A2 (pt) composto, composição farmacêutica, e, uso de um composto
TN2014000063A1 (en) Kinase inhibitor polymorphs
MA32508B1 (fr) Composes organiques
UA110338C2 (en) Chemical compounds
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
IN2014MN02126A (pt)
BR112012023910A2 (pt) preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
EA201171063A1 (ru) Фармацевтические составы олмесартана
AR074222A1 (es) Derivados lantibioticos carboxiamida con actividad antibacterial mejorada, procedimiento de obtencion sus composiciones farmaceuticas derivados carboxamida y empleo de los mismos
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VALEANT PHARMACEUTICALS INTERNATIONAL (US)

B25A Requested transfer of rights approved

Owner name: 1ST ORDER PHARMACEUTICALS, INC. (US)

B25A Requested transfer of rights approved

Owner name: XENON PHARMACEUTICALS, INC. (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 37/36

Ipc: C07D 217/04 (2006.01), A61K 31/175 (2006.01), A61K

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]